评估不同生物分子在 COVID-19 预防和治疗中的补充作用。
Assessment of Supplementation with Different Biomolecules in the Prevention and Treatment of COVID-19.
机构信息
Biomedical Group (BIO277), Department of Nursing, Faculty of Health Sciences, University of Granada, Avda. Ilustración 60, 18016 Granada, Spain.
Biomedical Group (BIO277), Department of Stomatology, School of Dentistry, University of Granada, 18016 Granada, Spain.
出版信息
Nutrients. 2024 Sep 11;16(18):3070. doi: 10.3390/nu16183070.
Consequences of the disease produced by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have led to an urgent search for preventive and therapeutic strategies. Besides drug treatments, proposals have been made for supplementation with biomolecules possessing immunomodulatory and antioxidant properties. The objective of this study was to review published evidence on the clinical usefulness of supplementation with vitamin D, antioxidant vitamins (vitamin A, vitamin E, and vitamin C), melatonin, lactoferrin and natural products found in food (curcumin, luteolin, ginger, allicin, magnesium and zinc) as supplements in SARS-CoV-2 infection. In general, supplementation of conventional treatments with these biomolecules has been found to improve the clinical symptoms and severity of the coronavirus disease (COVID-19), with some indications of a preventive effect. In conclusion, these compounds may assist in preventing and/or improving the symptoms of COVID-19. Nevertheless, only limited evidence is available, and findings have been inconsistent. Further investigations are needed to verify the therapeutic potential of these supplements.
由严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2)引起的疾病后果导致了对预防和治疗策略的紧急寻找。除了药物治疗外,还提出了补充具有免疫调节和抗氧化特性的生物分子的建议。本研究的目的是回顾已发表的关于补充维生素 D、抗氧化维生素(维生素 A、维生素 E 和维生素 C)、褪黑素、乳铁蛋白和食物中发现的天然产物(姜黄素、木犀草素、生姜、大蒜素、镁和锌)作为 SARS-CoV-2 感染补充剂的临床有用性的证据。一般来说,这些生物分子与常规治疗联合补充可改善冠状病毒病(COVID-19)的临床症状和严重程度,并有一些预防作用的迹象。总之,这些化合物可能有助于预防和/或改善 COVID-19 的症状。然而,目前只有有限的证据,而且结果不一致。需要进一步的研究来验证这些补充剂的治疗潜力。
相似文献
Nutrients. 2020-8-23
Ital J Pediatr. 2021-2-15
Int J Mol Sci. 2021-2-16
Infect Disord Drug Targets. 2023
Front Immunol. 2020-6-23